Home | Site Map | Contact Us |  Tell a Colleague | Print Page  
Valcyte valganciclovir HCI tablets Roche
About Roche Transplantation Research Resources for Professionals Prescribing Information Community Support Industry Events/News
Sign Up
Login Here
E-mail
Password
Forgot Password

Important Safety and Prescribing Information

CellCept Zenapax Valcyte Learn More about Product Pipeline

IV potency. Oral delivery.

Valcyte® valganciclovir HCl tablets offers powerful and convenient treatment of CMV retinitis in people living with AIDS.

 

Bioavailability
Ganciclovir bioavailability of ≈60%
Pharmacokinetic Profile
Ganciclovir exposure comparable to that achieved with IV ganciclovir
Indications
For the treatment of CMV retinitis in patients living with AIDS
Efficacy
Efficacy comparable to that of Cytovene-IV
Safety
Safety profile similar to that of ganciclovir
Dosing
IV potency with just 2 tablets
Formulation
Available as a 450 mg tablet for oral administration
Drug Interactions
Studies conducted with Valcyte and with ganciclovir
Product Information
Download the Complete Product Information.
Product Slide Kit
Coming Soon

  Safety

Privacy Statement  |  Legal Statement  |  Intended for U.S. Physician Audiences Only Copyright © 2006-2008 - Roche Laboratories Inc. All rights reserved.